Hsbc Holdings PLC Acquires 259,185 Shares of Hologic, Inc. (NASDAQ:HOLX)

Hsbc Holdings PLC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,034,651 shares of the medical equipment provider’s stock after purchasing an additional 259,185 shares during the quarter. Hsbc Holdings PLC owned 0.87% of Hologic worth $151,100,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new position in Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the first quarter valued at approximately $37,000. Cranbrook Wealth Management LLC acquired a new position in Hologic during the second quarter valued at approximately $47,000. Mather Group LLC. acquired a new position in Hologic during the first quarter valued at approximately $48,000. Finally, Massmutual Trust Co. FSB ADV grew its holdings in Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last quarter. 1.75% of the stock is currently owned by insiders.

Hologic Stock Performance

Shares of HOLX opened at $81.72 on Thursday. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The firm has a fifty day simple moving average of $80.51 and a 200 day simple moving average of $76.98. The stock has a market capitalization of $19.07 billion, a price-to-earnings ratio of 41.69, a PEG ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the company posted $0.93 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. Research analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HOLX. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Tuesday. Finally, Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.